Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-07-20 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis a requis auprès de la FDA une réunion de pré-soumission d’Autorisation d’Utilisation d’Urgence de Sarconeos (BIO101) dans le traitement du COVID-19
Regulatory Filings Classification · 95% confidence The document is a press release dated July 20, 2023, announcing that Biophytis has requested a pre-submission meeting with the FDA regarding an Emergency Use Authorization (EUA) for its drug candidate Sarconeos (BIO101) for severe COVID-19 treatment. This type of announcement, detailing a specific regulatory step or corporate action (like filing a request with a regulatory body), is typically classified as a general corporate update or regulatory filing announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific shareholder action (DIV, DVA), and it is not merely announcing the publication of another report (RPA), the most appropriate category is Regulatory Filings (RNS) as a general announcement of regulatory interaction. The length (6347 chars) suggests it is a substantive announcement, not just a brief notice.
2023-07-20 French
Biophytis Announces $3.8 Million Registered Direct Offering
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled as a "Press release" announcing a "Registered Direct Offering" of securities (ADSs, prefunded warrants, and ordinary warrants) resulting in gross proceeds of approximately $3.8 million. This activity directly relates to the company raising capital and changing its capital structure through the sale of securities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions SEC filings (Form F-3), the document itself is the announcement of the financing event, not the final prospectus or the full annual report.
2023-07-19 English
Biophytis annonce un Placement Direct Enregistré de 3,8 millions de dollars
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated July 19, 2023, announcing that Biophytis SA has entered into definitive agreements for a Registered Direct Offering and a concurrent Private Placement to raise approximately $3.8 million. The text details the structure of the offering (ADSs, pre-funded warrants, and common warrants), the pricing, the intended use of proceeds (R&D, clinical trials, working capital), and references the SEC registration statement (Form F-3) under which the offering is made. This content directly relates to the company's fundraising and capital structure activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP).
2023-07-19 French
Biophytis et SEQENS signent un partenariat pour la production du principe actif de Sarconeos (BIO101)
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a strategic partnership between Biophytis and SEQENS regarding the production of an active pharmaceutical ingredient (BIO101). This type of announcement, detailing business developments, partnerships, and strategic updates, is typically classified as a general corporate announcement. Since there is no specific category for 'Partnership Announcement' and it is not a formal regulatory filing like a 10-K, ER, or IR, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements that don't fit elsewhere, especially when they are press releases. It is not an Earnings Release (ER) as it focuses on a manufacturing deal, not financial results. It is not an Investor Presentation (IP) or Fund Factsheet (FS). It is a press release, not a formal report like 10-K or IR. Therefore, RNS is the best fit.
2023-07-18 French
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE DE BIOPHYTIS
Transaction in Own Shares Classification · 95% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE DE BIOPHYTIS" (Half-Year Balance Sheet of the Liquidity Contract of BIOPHYTIS) and is dated July 11, 2023, reporting figures as of June 30, 2023. It details the activity (purchases and sales of shares) under a liquidity contract over the first semester (H1) of 2023. This content relates to the company's financial status and operations over a specific interim period (six months), which strongly aligns with the definition of an Interim/Quarterly Report (IR). Although it focuses on a liquidity contract, the structure and period covered (semestriel/half-year) make it a comprehensive interim financial disclosure rather than just a brief announcement (RPA/RNS) or a management discussion (MDA). Since it covers a period shorter than a year, 'IR' is the most appropriate classification.
2023-07-11 Portuguese
Biophytis a demandé à la FDA l’autorisation de lancer l’étude SARA-31 de phase 3 dans la sarcopénie
Regulatory Filings Classification · 99% confidence The document is a press release dated July 10, 2023, announcing that Biophytis has submitted an application to the FDA to launch its Phase 3 study (SARA-31) for sarcopenia. This type of announcement, detailing clinical trial progress, regulatory submissions, and future plans, is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it focuses on a specific, material event (FDA submission for Phase 3 trial initiation) rather than a full set of periodic financial results (like 10-K or IR), and it is a formal announcement, 'ER' (Earnings Release) is the most appropriate classification, as these releases often contain significant operational and regulatory news alongside or instead of quarterly figures. It is not a transcript (CT), a formal annual report (10-K), or a simple notice of dividend (DIV). Given the content is a major operational update, ER fits best among the provided options, although RNS could be a fallback. I will classify it as ER as it is a significant, time-sensitive announcement typical of earnings-related communications.
2023-07-10 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.